Table 1

Diagnostic characteristics for SARS-CoV-2 rapid diagnostics – results are reported as published

TechnologyPopulationSensitivity % (95% CI)Specificity % (95% CI)Turnaround time
Antigen detection† (pooled)2272.0 (63.7 to 79.0)99.5 (98.5 to 99.8)
Panbio23 43Mixed74.5 (69.9 to 78.7)99.7 (99.3 to 99.9)15 min
BinaxNow44 45Symptomatic hospital patients74 (64 to 82)99.9 (97 to 100)15 min
Innova†23 24 46Asymptomatic40.0 (28.5 to 52.4)99.9 (99.8 to 99.99)
:
20 min
Symptomatic cohortLab scientists running tests, 79.0 (72 to 84); healthcare workers running tests, 70.0 (73 to 76)99.7 (99.5 to 99.8)
LumiraDx SARS-CoV-2 antigen test30Symptomatic hospital patients83.8 (76.4 to 89.2)97.6 (91.6 to 99.3)12 min
Direct molecular test† (pooled)2295.1 (90.5 to 97.6)98.8 (98.3 to 99.2)
OptiGene (saliva)32 33Mixed80 (72 to 85)100 (0.99 to 1.00)20 min
Abbott ID Now SARS-CoV-222 31 47Symptomatic hospital patientsMeta-analysis: 73.0 (66.8 to 78.4)
TVG evaluation: 93.2 (84.3 to 97.5)
Meta-analysis: 99.7 (98.7 to 99.9)22
TVG evaluation: 98.4 (96.5 to 99.3)
13 min
RT-PCR
 DNANudge COVID-1934 48Symptomatic hospital patients82.1 (77.7 to 85.7)99.1 (98.4 to 99.5)90 min
 Horiba POCKIT SARS-CoV-249Symptomatic hospital patients95.7 (91.0 to 98.1)97.7 (95.2 to 99.0)85 min
 SAMBA II SARS Co-V-2 test35Symptomatic hospital patients98.8 (NR)100 (NR)90 min
  • This seeks to be a list that is representative but not comprehensive; inclusion here is not an endorsement. The studies cited for diagnostic characteristics are from the UK’s TVG, published CONDOR evaluations and a Cochrane review. This table summarises data from studies with different methodologies including lab reviews and in context evaluations; it is not a complete review of all available literature. The FIND collaborative maintains a tracker of all available technologies available here https://wwwfinddxorg/covid-19/pipeline/.

  • *The Innova lateral flow test is currently one of the most studied in part due to its widespread deployment in the UK. The reported sensitivity varies; we report the range found in the published literature.

  • †Pooled data is referenced from the Cochrane review by Dinnes et al 22

  • CONDOR, COvid-19 National DiagnOstic Research and evaluation; NR, not reported; TVG, Technologies Validation Group.